News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Ark Therapeutics Pulls Cerepro Marketing Application in Europe
July 23, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Ark Therapeutics Group PLC has pulled its application for the early marketing approval of Cerepro, an experimental brain cancer treatment, after regulators confirmed more trial data are required.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Cancer
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
September 4, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
September 3, 2026
·
2 min read
·
Heather McKenzie
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
September 3, 2026
·
2 min read
·
Annalee Armstrong
Rare diseases
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review
September 3, 2026
·
2 min read
·
Tristan Manalac
